Dr. Michael Elman of Elman Retina Group, Baltimore, Maryland, presents 10 year data demonstrating that Preferential Hyperacuity Perimetry (the Foresee Device) is a valuable tool in early detection of neovascular AMD.

Dr. Susanna Park reviews current therapy of retinal branch and central vein occlusion and discusses a Phase I trial (the TRUST study) investigating the use of intravitreal autologous stem cells as a possible treatment for central vein occlusion. 

Dr. Susanna Park, Professor of Ophthalmology, Roth Endowed Chair in Visual Science at the University of California, Davis

We discuss a novel mechanism of action for the treatment of diabetic macular edema and neovascular AMD with Phase I/II trial results Dr. Raj Maturi, Midwest Eye Institute, Indiana University School of Medicine.

We review lesion progression in the eighteen month data with Roger Goldberg, MD, MBA of Bay Area Retina Associates, Walnut Creek, California.

We discuss the role that clinicians can play in fostering innovation in the retinal pharmacotherapy space with Dr. Eliot Lazar.

We discuss the 12 month results of the Phase I Davio Trial of an innovative TKI agent for the sustained treatment of neovascular AMD with Dr. Rishi Singh, Professor of Ophthalmology, Cole Eye Insitute, President, Cleveland Cllinic-Martin Hospital, Stuart, Florida.

We discuss treat and extend versus alternate dosing strategies to treat center involving diabetic macular edema with Dr. Varun Chaudhary, Chief of Ophthalmology, Hamilton Regional Eye Center and Professor, McMaster University.

We discuss the role of IOP pressure elevation following intravitreal anti-VEGF therapy with Parnian Arjmand, MD, MSC, FCSRS of the Toronto Retina Institute.

We discuss real world experience about faricimab with Dr. Carl Danzig of Pompano Beach, Florida.

We discuss new treatment options and clinical trials for radiation retinopathy with Prithvi Mruthyunjaya MD Professor of Ophthalmology, Stanford Medical School, Director of Ocular Oncology, Byers Eye Institute.